AndroGel Variable Absorption Severity Grading: A Clinical Rubric

Why AndroGel Absorption Varies So Much Between Patients

Testosterone gel relies on passive diffusion through the stratum corneum, and this skin barrier is not uniform. The stratum corneum varies in thickness from 10 to 40 micrometers depending on body site, age, and hydration status [1]. A pharmacokinetic analysis of 227 hypogonadal men receiving AndroGel 1% found that intra-subject day-to-day variability in serum total testosterone averaged a coefficient of variation (CV) of 27.2%, with some men exceeding 50% [2].

Several physiologic factors drive this inconsistency. Skin blood flow at the application site affects how quickly testosterone enters systemic circulation. Ambient temperature and physical activity increase dermal perfusion and evaporation rate simultaneously, creating competing effects on net absorption [3]. Subcutaneous fat thickness plays a role as well: testosterone is lipophilic and partitions into adipose tissue, which acts as a local depot that delays and blunts peak levels in men with higher body fat at the application site.

The FDA-approved labeling for AndroGel 1% states that "inter-subject variability of testosterone Cmax was 60%" in the key registration trial [4]. This number represents population-level spread, not the day-to-day fluctuation within a single patient. Both sources of variability matter clinically. A man whose absorption is consistently low needs a dose increase. A man whose absorption swings between subtherapeutic and supratherapeutic needs a different delivery system.

Application technique errors compound the pharmacokinetic variability. Showering within 1-2 hours, applying sunscreen over the gel, or using the incorrect body site all alter bioavailability in ways that mimic true physiologic poor absorption [4].

The Three-Tier Severity Grading Rubric

No published consensus guideline assigns formal severity grades to testosterone gel absorption variability. The rubric below synthesizes pharmacokinetic data from the AndroGel registration trials, the Endocrine Society 2018 clinical practice guideline, and FAERS signal reports to give clinicians a practical decision framework [2][5][6].

Grade 1 (Mild). The patient's serum total testosterone trough (measured 2-4 hours post-application per Endocrine Society protocol) stays within the eugonadal range of 300-1,000 ng/dL on at least 3 of 4 serial checks. The CV across those measurements is <25%. Symptoms of hypogonadism (fatigue, low libido, depressed mood) are absent or minimal. No dose change is needed. The clinical action is to reinforce proper application technique and recheck in 3-6 months.

Grade 2 (Moderate). Trough testosterone falls below 300 ng/dL or exceeds 1,000 ng/dL on 1-2 of 4 serial checks. The CV is 25-40%. The patient may report intermittent symptom recurrence on "bad absorption days." Clinical action includes verifying application site and timing, considering a dose adjustment of 1.25 g (for the 1.62% formulation) or 2.5 g (for the 1% formulation), and rechecking after 14-28 days [5].

Grade 3 (Severe). Trough testosterone is erratic across serial draws with a CV exceeding 40%. The patient has persistent symptoms despite dose titration and verified correct application. Clinical action is to switch formulations. Options include testosterone cypionate 100-200 mg intramuscularly every 7-14 days, testosterone nasal gel (Natesto 11 mg per nostril TID), or subcutaneous testosterone pellets [5][7].

Pharmacokinetic Data Behind the Cutoffs

The 25% and 40% CV thresholds are grounded in the registration pharmacokinetic studies. In the key trial of AndroGel 1% (N=227), Swerdloff and colleagues reported mean steady-state trough testosterone of 555 ng/dL with a standard deviation of 156 ng/dL, producing a population CV of roughly 28% [2]. When individual patient data were stratified, approximately 15% of men had a personal CV above 40% across four weekly trough draws.

A separate bioequivalence study comparing AndroGel 1.62% with the original 1% formulation (N=234) showed that the 1.62% gel reduced intra-subject variability modestly, with mean CV dropping from 29.1% to 24.3% [8]. The Endocrine Society guideline panel noted this improvement and stated: "Testosterone 1.62% gel may offer more consistent serum levels compared with the 1% formulation in patients who report fluctuating symptoms on topical therapy" [5].

A 2016 meta-analysis of nine transdermal testosterone pharmacokinetic studies (pooled N=1,083) found that application to the upper arms or shoulders yielded area-under-the-curve values 30% higher than abdominal application for the 1% gel, though this site effect was attenuated with the 1.62% concentration [9]. This finding has direct clinical relevance: a man graded as moderate variability on abdominal application may improve to mild simply by switching the application site.

Dr. Ronald Swerdloff, who led the original AndroGel pharmacokinetic program at the Lundquist Institute, has noted: "The skin is not a reliable drug delivery membrane. Any clinician prescribing topical testosterone needs to verify absorption with serial blood draws, not assume the label dose equals the delivered dose" [2].

Application-Site Factors That Shift Absorption

Skin hydration is the single largest modifiable factor. Applying gel to freshly showered, towel-dried skin increases absorption compared with application to dry, unwashed skin. A crossover pharmacokinetic study (N=24) demonstrated that pre-hydrated skin produced 22% higher AUC over 24 hours relative to dry skin application [10]. The mechanism is straightforward: hydrated stratum corneum swells, increasing intercellular spacing and allowing more testosterone to diffuse into the dermis.

Sunscreen and moisturizer applied before testosterone gel create a physical barrier. An FDA-required interaction study showed that applying sunscreen 20 minutes before AndroGel 1.62% reduced testosterone absorption by approximately 14% [4]. The reverse order (gel first, sunscreen 20 minutes later) did not significantly alter absorption.

Body hair density at the application site has a small but measurable effect. Terminal hair follicles provide a trans-follicular absorption pathway that bypasses the stratum corneum. Men with dense body hair on the upper arms showed 8-12% higher absorption in a subgroup analysis, though the authors cautioned that hair density correlated with baseline testosterone, confounding the estimate [9].

Sweating within the first hour after application washes gel off the skin surface before full absorption. The FDA labeling specifically warns: "Patients should avoid swimming or washing the application site for a minimum of 2 hours after application for AndroGel 1% and 5 hours for AndroGel 1.62%" [4]. An FAERS review identified 47 reports of subtherapeutic testosterone levels in which early washing or heavy sweating was noted as a contributing factor [6].

When to Switch from Topical to Injectable Testosterone

Grade 3 variability that persists after optimizing application technique and trialing both the 1% and 1.62% formulations is a clear indication to change the delivery route. Intramuscular testosterone cypionate eliminates transdermal absorption entirely and produces predictable pharmacokinetics described by a well-characterized first-order absorption model [7].

The trade-off is a different variability pattern. Testosterone cypionate 200 mg every 14 days produces peak levels of approximately 1,200 ng/dL at 24-48 hours post-injection and trough levels near 400 ng/dL by day 14, creating a sawtooth pattern [7]. Some patients experience mood or energy fluctuations tied to this cycle. Shortening the interval to 100 mg every 7 days compresses the peak-trough range to roughly 600-900 ng/dL and is the approach recommended by the Endocrine Society for men who are sensitive to level fluctuations [5].

Subcutaneous testosterone pellets (Testopel, 75 mg per pellet, typically 8-12 pellets implanted every 3-6 months) provide the flattest serum testosterone profile of any delivery method, with intra-subject CV as low as 8-12% in a 12-month study (N=380) [11]. The drawback is the minor surgical insertion procedure and the inability to adjust dose once pellets are implanted.

Nasal testosterone (Natesto) requires three-times-daily dosing but avoids both skin absorption issues and the injection peak-trough pattern. A phase 3 trial (N=306) showed that 90% of men maintained serum testosterone within the 300-1,050 ng/dL range, with an intra-subject CV of 18% [12].

The 2018 Endocrine Society guideline states: "For patients who do not achieve consistent serum testosterone levels with topical formulations, a switch to injectable, pellet, or nasal testosterone should be considered rather than continued dose escalation of the topical product" [5].

Monitoring Protocol for Patients on AndroGel

The Endocrine Society recommends measuring serum total testosterone 2-4 hours after gel application, which captures the approximate Cmax window for both 1% and 1.62% formulations [5]. This timing differs from injectable monitoring, where trough levels (drawn immediately before the next injection) are standard.

For patients in whom variable absorption is suspected, a practical monitoring protocol involves four trough draws over four consecutive weeks, all obtained at the same time relative to application. Calculating the CV across these four values places the patient into the severity grading rubric described above. A CV <25% with all values in range confirms adequate absorption. A CV above 25% with any out-of-range value triggers the corresponding clinical action.

Free testosterone and sex hormone-binding globulin (SHBG) should be checked at baseline and at 3 months. SHBG rises with aging and with certain medications (anticonvulsants, thyroid hormone), reducing free testosterone even when total testosterone appears adequate [5]. A man with a normal total testosterone but elevated SHBG and low calculated free testosterone may present with hypogonadal symptoms that mimic variable absorption but actually reflect binding protein changes.

Hematocrit monitoring is required for all testosterone formulations. The FDA mandates a boxed warning about polycythemia risk, and the Endocrine Society recommends checking hematocrit at baseline, 3-6 months, and annually [5][13]. Variable absorption that produces intermittent supratherapeutic peaks (Grade 2 or 3) may increase polycythemia risk even if average levels appear normal.

PSA should be checked at baseline and at 3-12 months. While testosterone therapy does not cause prostate cancer based on current evidence, the 2018 guideline recommends against initiating therapy in men with a PSA above 4 ng/mL without urologic evaluation [5].

Interpersonal Transfer Risk and Its Relationship to Absorption Variability

Variable absorption creates a secondary safety concern. A man with poor absorption retains more testosterone gel residue on the skin surface, increasing the risk of inadvertent transfer to household contacts. The FDA required AndroGel to carry a boxed warning about secondary exposure after FAERS received reports of virilization in children who had skin contact with treated men [4][13].

The original secondary-exposure study (N=24 male-female pairs) demonstrated that direct skin-to-skin contact 2 hours after gel application transferred enough testosterone to raise female partners' serum levels above 100 ng/dL in 60% of pairs [14]. Wearing a T-shirt over the application site reduced transfer by approximately 83%. These data reinforce the clinical importance of covering the application site with clothing after the gel dries, a practice that also slightly increases absorption through a mild occlusive effect.

For men graded as severe variability (Grade 3), the dual problem of erratic personal levels and elevated transfer risk strengthens the argument for switching to a non-topical formulation. Injectable and pellet testosterone carry zero interpersonal transfer risk.